STAA

Analyst Note: STAA (STAAR Surgical Company)

Date: 2026-06-20 Event Date: 2026-06-20

1. Structural Readiness

Conservative Entry: $32.01 Current Price: $29.12 Extension: -9.0% vs. conservative entry Breakout Level: $32.01 (Conservative Entry) ATR at Breakout: 5.0% (High) Current ATR: 4.0% (High) Pivot Strength: Swing Cap Bucket: Small

Setup Classification: The setup is currently FORMING.

2. Thesis Layer

Thesis Classification: TACTICAL / Setup-Led Secular Thesis: None named at this date. Analysis: As of June 20, 2026, there is no named macro or secular thesis driving this specific trade. The conviction must be derived entirely from the quality of the structural setup (the forming coil) and the underlying business fundamentals reported in the most recent filings. We are not assigning a "growth" or "recovery" label based on external narratives but are judging the name strictly on the strength of the earnings data and the technical structure. The setup is the primary driver; the business fundamentals serve as the conviction weight for the setup's validity.

3. The Business

Company Overview: STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems. The company's principal products are Implantable Collamer Lenses (ICLs) used in refractive surgery. Business Model: The company operates on a global sales model, with the vast majority of revenue generated outside the United States. Key Fundamentals (as of May 13, 2026):

• Revenue Growth: In the first quarter of fiscal 2026, net sales reached $93.5 million, representing an 119.6% year-over-year increase. This growth was driven by strong sales in China and double-digit growth in the Americas.
• Profitability Turnaround: The company reported a meaningful improvement in profitability, with adjusted EBITDA turning positive at $24.4 million, compared to an adjusted EBITDA loss of $26.3 million in the prior year quarter.
• Geographic Concentration: China remains a critical market, accounting for 51% of net sales in the first quarter ($47.4 million). Two China distributors accounted for approximately 32% of consolidated net sales during fiscal 2025.
• Product Milestones: In February 2026, the company announced the sale of more than 4,000,000 ICLs worldwide.
• Regulatory Expansion: In April 2026, the FDA approved an expansion of the EVO ICL indication to patients aged 45 to 60, increasing the addressable market.
• Manufacturing & Supply Chain: The company manufactures in the United States and Switzerland. The Nidau, Switzerland facility is scaling and is planned to supply 100% of EVO and EVO+ lenses shipped to China in 2026 without import tariffs. To mitigate tariff exposure, the company implemented consignment agreements with Chinese distributors in April 2025, delivering inventory in advance of tariff implementation.
• Inventory Status: As of January 2, 2026, finished goods inventory was $39.7 million, representing 219 Days' Inventory on Hand (DOH).

4. Archetype and Conviction

Archetype: Quality Compounder (with inflection characteristics) Rationale: The company fits the "Quality Compounder" archetype due to its transition from a loss-making entity to a profitable one, evidenced by the positive adjusted EBITDA of $24.4 million in Q1 2026. The 119.6% YoY revenue growth and the milestone of 4 million lenses sold indicate a scaling business model with strong secular tailwinds in lens-based refractive surgery. The expansion of the FDA indication to a broader age demographic (45-60) supports long-term compounding potential.

Conviction Stack:

• Thesis Strength: Moderate (Tactical setup, no external macro thesis).
• Evidence Quality: High. The earnings transcript and SEC filings provide concrete data on revenue doubling, profitability turning positive, and specific operational milestones (4M lenses, FDA expansion).
• Structural Quality: High. The ATR at breakout (5.0%) and current ATR (4.0%) fall into the "high" bucket (4-6%), which is the historical sweet spot for structural quality. This indicates the stock has the volatility necessary to move significantly once the breakout occurs, without being in the "extreme" danger zone (>8%).
• Rerating Potential: High. The shift from negative to positive EBITDA, combined with the 119% revenue growth, suggests a fundamental re-rating is underway, provided the supply chain (Swiss facility) and regulatory (FDA) drivers continue to execute as management expects.

5. Invalidations, Strengtheners, and Gaps

Strengtheners: A daily close above the conservative entry of $32.01 would confirm the breakout, transitioning the coil to "Confirmed-Active." Continued sequential revenue growth and sustained positive EBITDA in subsequent quarters would further strengthen the fundamental case. Gaps in Evidence:

• Inventory Turnover: The Days' Inventory on Hand (DOH) of 219 days as of January 2026 is elevated. While the company cites consignment inventory as a factor, the high DOH warrants monitoring to ensure it does not indicate slowing demand or overstocking issues as the company scales.
• Customer Concentration: The heavy reliance on two China distributors (51% of Q1 sales) presents a concentration risk that is not fully mitigated by the consignment agreements alone, though the tariff mitigation strategy is a positive structural change.
• Forward Guidance Specifics: While management provided context on the Swiss facility scaling, specific quantitative guidance for the full fiscal year 2026 regarding the impact of the new FDA indication on revenue mix is not detailed in the provided evidence.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key risks: 219 Days' Inventory on Hand suggests potential overstocking or demand softness; Heavy reliance on China distributors (51% of sales) creates concentration risk; Setup is forming, not confirmed, requiring a breakout above $32.01 to be actionable. Sizing hint: Position size should be conservative given the "forming" state and high ATR volatility; wait for breakout confirmation before adding size. Expected path: Management expects the Swiss facility to supply 100% of China shipments tariff-free in 2026; if sales continue to scale with the new indication, the stock should test the $32.01 breakout level. Expected horizon: 3 to 6 months for the setup to resolve (breakout or invalidation).